Severe liver injury after initiating therapy with atomoxetine in two children

Journal of Pediatrics

Volumn 148, Issue 6, 2006, Pages 831-834

  Lim, Joel R ^a   Faught, Philip R ^a   Chalasani, Naga P ^a   Molleston, Jean P ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ABDOMINAL PAIN; ACUTE HEPATITIS; ANKLE PAIN; ARTICLE; ATTENTION DEFICIT DISORDER; AUTOIMMUNE HEPATITIS; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; CONVALESCENCE; CORTICOSTEROID THERAPY; DIAGNOSTIC VALUE; DIARRHEA; DRUG FEVER; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAUNDICE; KNEE PAIN; LIVER BIOPSY; LIVER INJURY; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; VOMITING;

ADRENERGIC UPTAKE INHIBITORS; CHILD; CYTOCHROME P-450 CYP2D6; FEMALE; HEPATITIS, AUTOIMMUNE; HEPATITIS, TOXIC; HUMANS; PROPYLAMINES;

EID: 33745049231     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.01.035     Document Type: Article

References (19)

1. US Food and Drug Administration. Available at http://www.fda.gov/medwatch/SAFETY/2004/Strattera_PI.pdf. Accessed March 2005.
2. Ring B.J., Gillespie J.S., Eckstein J.A., and Wrighton S.A. Identification of the human Cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 30 (2002) 319-323
3. Guengerich FP. Human cytochrome P450 enzymes. In Ortix de Montellano PR, ed. Cytochrome P450: Structure, Mechanism and Biochemistry. 2nd ed. New York: Plenum Press:473-535.
4. st ed. New York: Marcel Dekker, Inc.:471-504.
5. Sauer J., Ring B., and Witcher J.W. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 44 (2005) 571-590
6. Zimmerman H.J. Drug-induced liver disease. Clin Liver Diseases 4 (2000) 73-96
7. US Food and Drug Administration. Available at http://www.fda.gov/cder/foi/label/2002/214 11_strattera_lbl.pdf. Accessed June 2004.
8. Dan G., and Benichou C. Causality assessment of adverse reaction to drugs: a novel method based on the conclusions of international consensus meetings: application to drug induced liver injury. J Clin Epidemiol 46 (1993) 1323-1330
9. Benichou C., Danan G., and Flahault A. Causality assessment of adverse reactions to drugs, II: an original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 46 (1993) 1331-1336
10. Siddiqui J., Raina D., Abraham A., Alla V., Chalasani N., Wu G.Y., et al. Autoimmune hepatitis induced by statins. Gastroenterology 128 (2005) A171
11. Thiim M., and Friedman L.S. Hepatotoxicity of antibiotics and anti-fungals. Clin Liver Disease 7 (2003) 381-399
12. Villeneuve J.P., and Pichette V. Cytochrome P-450 and liver disease. Curr Drug Metab 5 (2004) 273-282
13. Sugimura T., Obermayer-Straub P., Kayser A., Braus S., Loges S., Alex B., et al. A major CYP2D6 autoepitope in autoimmune Hepatitis type 2 and chronic hepatitis C. is there a three-dimensional structure homologous to other cytochrome P450 autoantigens?. Autoimmunity 35 (2002) 501-513
14. Rizzetto M., Swana G., and Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol 15 (1973) 331-344
15. Alvarez F., Bernard O., Homber J.C., and Kreibich G. Anti-liver kidney microsomal antibody recognizes a 50,000 molecular weight protein of the endoplasmic reticulum. J Exp Med 161 (1985) 1231-1236
16. Liu Z.X., and Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 6 (2002) 735-774
17. US Food and Drug Administration. Available at http://www.fda.gov/bbs/topics/answers/2004/ANSO1335.html. Accessed March 2005.
18. Eli Lilly. Available at http://www.lillytrials.com/results_files/Strattera_summary_4642.pdf. Accessed February 2005.
19. Safer D.J., Zito J.M., and Gardner J.F. Pemoline hepatotoxicity and post-marketing surveillance. J Am Acad Child Adolesc Psychiatry 40 (2001) 622-629